Isabel C Arrillaga-Romany
Overview
Explore the profile of Isabel C Arrillaga-Romany including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nelson T, Murthy N, Martinez-Lage M, Abramson J, Branagan A, Ji Y, et al.
Neurology
. 2025 Feb;
104(6):e213393.
PMID: 39977718
No abstract available.
2.
Nelson T, Murthy N, Martinez-Lage M, Martinez-Lage Alvarez M, Abramson J, Branagan A, et al.
Neurology
. 2024 Oct;
103(9):e209929.
PMID: 39365973
No abstract available.
3.
Karschnia P, Arrillaga-Romany I, Eichler A, Forst D, Gerstner E, Jordan J, et al.
Neuro Oncol
. 2023 Jul;
25(12):2239-2249.
PMID: 37402650
Background: Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established as a leading engineered T-cell therapy for B-cell lymphomas; however, data for patients with central nervous system (CNS) involvement...
4.
Ly K, Richardson L, Liu M, Muzikansky A, Cardona J, Lou K, et al.
Clin Cancer Res
. 2023 Jun;
29(16):3017-3025.
PMID: 37327319
Purpose: We evaluated the efficacy of bavituximab-a mAb with anti-angiogenic and immunomodulatory properties-in newly diagnosed patients with glioblastoma (GBM) who also received radiotherapy and temozolomide. Perfusion MRI and myeloid-related gene...
5.
Gonzalez Castro L, Arrillaga-Romany I, Batchelor T
JAMA Neurol
. 2023 Jan;
80(3):227-228.
PMID: 36648934
No abstract available.
6.
Brastianos P, Kim A, Giobbie-Hurder A, Quant Lee E, Wang N, Eichler A, et al.
Nat Commun
. 2022 Mar;
13(1):1325.
PMID: 35289329
High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their aggressive...
7.
Bouffard M, Chwalisz B, Romero J, Arrillaga-Romany I, Massoth L
N Engl J Med
. 2021 Feb;
384(8):745-753.
PMID: 33626257
No abstract available.
8.
Chi A, Cahill D, Reardon D, Wen P, Mikkelsen T, Peereboom D, et al.
JCO Precis Oncol
. 2020 Sep;
4.
PMID: 32923886
Purpose: Despite the high frequency of genetic alterations in glioblastoma (GBM), EGFR-targeted therapies have not had success in this disease. To improve the likelihood of efficacy, we targeted adult patients...
9.
Alexander B, Trippa L, Gaffey S, Arrillaga-Romany I, Lee E, Rinne M, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32914038
Purpose: Adequately prioritizing the numerous therapies and biomarkers available in late-stage testing for patients with glioblastoma (GBM) requires an efficient clinical testing platform. We developed and implemented INSIGhT (Individualized Screening...
10.
Jordan J, Miller J, Cushing T, Seijo M, Batchelor T, Arrillaga-Romany I, et al.
Neurooncol Pract
. 2019 Aug;
5(1):64-68.
PMID: 31385986
Background: Treatment of aggressive pituitary adenomas typically involves a multimodality approach based on histopathological features and may include pharmacotherapy, surgery, and occasionally radiation therapy. In cases of treatment-refractory tumor progression,...